Pharma's Almanac: Nice Insight's Content Community

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Tanvex CDMO’s Anke Hartung, Ph.D., discusses her team’s development of novel analytical tools to assess the enhancement of the antibody-dependent cellular cytoxicity response of an anticancer monoclonal antibody drug.

Optimized Residual dsRNA Detection for mRNA Therapeutics

RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

A team of experts from Samsung Biologics discusses the company’s development of a superior ELISA-based method for dsRNA detection that ensures greater accuracy and reliability.

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Cell Therapy

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

In this Q&A, OrganaBio’s Chief Executive Officer Justin Irizarry discusses the strategies and operational philosophies driving the company and how it plans to navigate future challenges and opportunities in the rapidly evolving cell therapy landscape.

Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Touchlight’s Elena Stoyanova, Ph.D., and Tom Adie, Ph.D., explain how the company’s new nonviral MegaBulb DNA (mbDNA) offers a high-purity, synthetic CRISPR ssDNA template that demonstrates remarkable efficiency and minimal toxicity.

Ophthalmology

Sep 16, 2024

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Tracey Roberts, Jennifer Christiansen, Ph.D., and Debra Schaumberg, Sc.D., O.D., all with the PPD™ clinical research business of Thermo Fisher Scientific, discuss the growth and challenges of global, late-stage ophthalmology clinical trials and the key drivers of proactive planning for success.

News

Financing

Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets™

Biologics

Chime Biologics and MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing

Financing

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline

Clinical Trials

Oct 28, 2024

TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance

Preclinical Data

Oct 25, 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene for the Treatment of Hereditary Angioedema

Clinical Data

Oct 25, 2024

Skyhawk Therapeutics Presents Compelling Preclinical Data at the Molecular Targets and Cancer Therapeutics Symposium

The Road to the Max: Australia

Top 5

dbDNA

Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA

Top 5

Women's Health

Jul 09, 2024

Revolutionizing Biologics (and Biology) through a Focus on Women

RoundTable

View all roundtable

RoundTable Topics

Milestones

What important company milestone do you anticipate reaching in 2022?

Alen Guy, Ph.D.

Anna Dormady

Dago Caceres

David W. Freidinger

Jeff Elton

In 2022, the Pharma Business group will be putting more choices, solutions, and resources directly in the hands of customers through an innovative approach to our website.

View all Answers

RoundTable

View all roundtable

Milestones

What important company milestone do you anticipate reaching in 2022?

Alen Guy, Ph.D.

Anna Dormady

Dago Caceres

David W. Freidinger

Jeff Elton

In 2022, the Pharma Business group will be putting more choices, solutions, and resources directly in the hands of customers through an innovative approach to our website.

View all Answers

RoundTable Topics

Milestones

Dealing with a Crisis

Personalized and Precision Medicine

Virtual BD and Marketing

Post-COVID-19 Supply Chain

Digital Connections

2021 Projections

Unmet medical needs

Evolving Technologies

Predictions

Challenges

U.S. Market

Leadership

Global Access

Lessons from the Pandemic

Regulatory

Sustainability

Social Media Marketing

Therapeutic Areas

Investment Trends

Year in Review

Innovation

Outsourcing Dynamics

Now Trending

Commercialization

Sep 17, 2024

Development Strategies for Overcoming Commercialization Challenges

Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

DoE for Clone Selection and Process Development to Meet Biosimilar Critical Qualities Attributes and High Productivity

Biosimilars

Sep 12, 2024

DoE for Clone Selection and Process Development to Meet Biosimilar Critical Qualities Attributes and High Productivity

Transforming Precision Medicine through a High-Resolution Temporal Exposome Platform

Exposomics

Sep 05, 2024

Transforming Precision Medicine through a High-Resolution Temporal Exposome Platform

Nanocarriers to Overcome the Blood–Brain Barrier (BBB)

Drug Delivery

Aug 30, 2024

Nanocarriers to Overcome the Blood–Brain Barrier (BBB)

Biotech

Sep 23, 2024

Five Small Biotechs to Watch: October 2024

Process Development

Sep 24, 2024

Economic Benefits of Digital Process Development

Ophthalmology

Sep 16, 2024

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

Expansion

Sep 09, 2024

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

Transforming Drug Development through a Female Perspective

Female-Centric

Sep 10, 2024

Transforming Drug Development through a Female Perspective

Cell Therapy

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Biopharma

Sep 27, 2024

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Bioassays

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Revolutionizing Biologics (and Biology) through a Focus on Women

Women's Health

Jul 09, 2024

Revolutionizing Biologics (and Biology) through a Focus on Women

RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Developability

Sep 04, 2024

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Videos

View all videos

Failure to Launch

Aug 07, 2024

Disaster Strikes

In episode 4 of the Road to Launch, disaster strikes, ending the race prematurely.

Failure to Launch

Aug 07, 2024

Disaster Strikes

Preparing to Launch

Aug 07, 2024

Preparing the Yacht for the Race

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Immuno-Oncology

May 24, 2022

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Stem Cell Therapy

Dec 12, 2023

Designing A Recipe for Stem Cell Therapy Success

Decentralized Clinical Trials

Nov 17, 2022

The Evolving Role of Remote Monitoring

Meet the Crew

Aug 07, 2024

Assembling the Crew

Transforming Market Insights into Growth

Marketing

May 09, 2022

Transforming Market Insights into Growth

Setting Sail

Aug 07, 2024

Sailing into the Trade Winds

Supply Chain

Dec 12, 2023

Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience

The Power of Aqueous Detergents in Critical Cleaning

Aqueous Cleaning

Dec 05, 2023

The Power of Aqueous Detergents in Critical Cleaning

Biologics CDMO

Jan 26, 2022

Growing as a Trusted, Dedicated Commercial Biologics CDMO

Data Connectivity

Jan 19, 2022

Discussing the Advancements in Oncology

In Focus

Pharmacovigilance

Jun 05, 2024

Navigating Shifting Requirements and an Explosion of Data in Pharmacovigilance

Clinical Trials

May 30, 2024

Optimizing Oncology and Rare Disease Clinical Trials by Focusing on Science and Aligning with both Patients and Investigators

Managing Complex Sample and IP Logistics in Support of Cell and Gene Therapies

Cell and Gene Therapy

Jul 09, 2024

Managing Complex Sample and IP Logistics in Support of Cell and Gene Therapies

Ophthalmology

Sep 16, 2024

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Biosimilars

Jul 16, 2024

Navigating the Global Regulatory Landscape for Biosimilars

Harnessing Longitudinal Data for Better Healthcare Outcomes in Long-Term Care

Real-World Data

Aug 26, 2024

Harnessing Longitudinal Data for Better Healthcare Outcomes in Long-Term Care

Latest

View all latest

QbD

Designing Quality into Biomanufacturing

Clinical Trials

Passion and Understanding Essential for Rare Disease Clinical Trials

Cleaning

Kicking off Road to the Max

Fill/Finish

Academia CDMO Clinical CRO Drug Discovery Early R&D Excipients / Intermediates Financing Equipment Preclinical CRO Supply Chain Technology

Superior Performance of SaniSure® Pharm-A-Clear LH® Tubing in Extended Fill/Finish Applications

Innovation

Oct 28, 2024

How is the pharmaceutical industry integrating innovations from adjacent industries to enhance drug development and production?

BIOSECURE Act

Oct 28, 2024

Can you discuss the anticipated impacts of the BIOSECURE Act on the biopharmaceutical landscape?

Advanced Therapies

Oct 25, 2024

A New Vision for Progressing Advanced Therapies

Oncology Trials

Oct 22, 2024

Navigating the Complex Landscape of Oncology Trials

Areas of Interests

A comprehensive market analysis with 110 major company profiles and detailed CDMO pricing information.

Over 60 company profiles covering the leading mRNA and LNP contract manufacturing organizations. Unique pricing comparison for the end-to-end manufacturing process.

Optimize your manufacturing process using 50+ established CDMO overviews and a requisite pricing study for small, mid sized and large manufacturers.

Comprehensive analysis of mammalian cell culture CDMOs including price benchmarking, market trends and over 80 company profiles.

Over 80 company profiles and analysis of leading microbial fermentation CDMO; exclusive market analysis and price comparison.

Understand the emerging ADC market with profiles on 30 notable CDMOs and an analysis of the value chain of mAbs, linkers and payloads. Benchmark with robust manufacturing pricing.

Exclusive pricing from 20+ CDMOs and market insight for pDNA as a reagent for advanced therapies and as a primary therapeutic.

Robust analysis of gene therapy market, includes 50 company profiles of AAV, Lentiviral and non-viral gene therapy CDMOs.

Discover the cell therapy market with unique insights, analysis, and overviews of allogeneic and autologous cell therapy CDMOs.

Over 80 extensive CDMO profiles for an all-encompassing benchmarking report. Exclusive pricing comparison and updated global GMP regulatory landscape

Discover the cell therapy market with unique insights, analysis, and overviews of allogeneic and autologous cell therapy CDMOs.